A limitation of the present study is the lack of in-depth investigation into the underlying mechanisms of hiPSC-CF-ECM's therapeutic effects and its immunological safety assessment in the rat MI model, as this was beyond the scope of the proof-of-concept animal experiment design. This evidence concerns the gene CFTR and myocardial infarction.